Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination.

Münzel EJ, Wimperis JZ, Williams A.

BMJ Case Rep. 2013 Feb 14;2013. pii: bcr2012007936. doi: 10.1136/bcr-2012-007936.

2.

The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.

Kieseier BC.

Expert Rev Neurother. 2014 Jan;14(1):105-20. doi: 10.1586/14737175.2014.869478. Review.

PMID:
24417500
3.

Psoriasis during interferon beta treatment for multiple sclerosis.

La Mantia L, Capsoni F.

Neurol Sci. 2010 Jun;31(3):337-9. doi: 10.1007/s10072-009-0184-x.

PMID:
19924503
4.

Interferon beta-1b (Extavia) for multiple sclerosis.

[No authors listed]

Med Lett Drugs Ther. 2010 Nov 1;52(1350):86-7. No abstract available.

PMID:
21045760
5.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147.

PMID:
20488825
6.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

7.

Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.

Thouvenot E, Carlander B, Camu W.

Expert Rev Neurother. 2012 Nov;12(11):1283-91. doi: 10.1586/ern.12.122. Review.

PMID:
23140228
8.

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.

Nikfar S, Rahimi R, Abdollahi M.

Clin Ther. 2010 Oct;32(11):1871-88. doi: 10.1016/j.clinthera.2010.10.006. Review.

PMID:
21095482
9.

Gender effects on treatment response to interferon-beta in multiple sclerosis.

Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

Acta Neurol Scand. 2014 Dec;130(6):374-9. doi: 10.1111/ane.12277.

PMID:
25208455
10.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators..

Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Erratum in: Lancet Neurol. 2010 Aug;9(8):759. Wadinger, K [corrected to Wandinger, K].

PMID:
20163990
11.

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.

Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group..

Mult Scler. 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309.

PMID:
19995846
12.

Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.

Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, La Mantia L, Repice A, Solari A, Tedeschi G, Milanese C.

PLoS One. 2014 Nov 17;9(11):e113371. doi: 10.1371/journal.pone.0113371.

13.

Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.

Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z; Interferon Beta-1b Multiple Sclerosis Study Group of Japan..

Neurology. 2005 Feb 22;64(4):621-30.

PMID:
15728282
14.

Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.

Korporal M, Haas J, Balint B, Fritzsching B, Schwarz A, Moeller S, Fritz B, Suri-Payer E, Wildemann B.

Arch Neurol. 2008 Nov;65(11):1434-9. doi: 10.1001/archneur.65.11.1434.

PMID:
19001161
15.

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.

Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C; QUASIMS Study Group..

J Neurol. 2007 Jan;254(1):67-77.

PMID:
17273808
16.

Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.

Bălaşa R, Bajko Z, Huţanu A.

Mult Scler. 2013 Jun;19(7):885-90. doi: 10.1177/1352458512468497.

PMID:
23207971
17.

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.

Lancet Neurol. 2009 Jun;8(6):519-29. doi: 10.1016/S1474-4422(09)70085-7.

PMID:
19409854
18.

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.

Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.

Lancet Neurol. 2010 Jul;9(7):672-80. doi: 10.1016/S1474-4422(10)70132-0. Erratum in: Lancet Neurol. 2010 Aug;9(8):759.

PMID:
20542736
19.

Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.

Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.

Mult Scler. 2012 Aug;18(8):1125-34. doi: 10.1177/1352458511433304.

PMID:
22194217
20.

The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.

Paolicelli D, D'Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavolpe V, Trojano M.

J Neurol. 2013 Jun;260(6):1562-8. doi: 10.1007/s00415-012-6829-3.

PMID:
23417273
Items per page

Supplemental Content

Support Center